Last week, Protavio was proud to support and participate in the 7th Advances in Circulating Tumor Cells meeting: “Liquid Biopsy: from Bench to Bedside”, held September 24th to 27th, 2025 in Thessaloniki. As event sponsors, we joined a global community of clinicians, researchers, and technology providers advancing the science and clinical impact of liquid biopsy.
Throughout the four-day program, delegates discussed state-of-the-art methods and clinical applications spanning CTCs, ctDNA and extracellular vesicles, with dedicated sessions on early detection, minimal residual disease, treatment monitoring, and real-world implementation and standardization. These conversations align with Protavio’s mission to enable robust, translational multi-omics and precision oncology solutions that move discoveries from bench to bedside.
As key takeaways, first, clinical momentum for liquid biopsy continues to build, with growing evidence and technical maturity accelerating adoption across cancer types, from screening to therapy selection and resistance monitoring. Second, quality and standards matter. Pre-analytical variables, assay validation and harmonization repeatedly surfaced as essentials for reliable clinical deployment, areas where Protavio’s focus on reproducibility and interoperability directly supports researchers and clinical labs. Third, collaboration is critical. ACTC fosters cross-sector partnerships, exactly the ecosystem needed to translate cutting-edge research into patient benefit.
We’re grateful to everyone who visited our stand to exchange ideas and map next steps in liquid-biopsy research and precision oncology. We extend our thanks to the organizers and the wider scientific community for an inspiring and impeccably run meeting in Thessaloniki. We were delighted to connect with partners old and new, explore collaborative opportunities, and share how Protavio supports rigorous liquid-biopsy research and clinical workflows. We look forward to continuing these conversations and contributing to the next wave of innovation in circulating biomarker science.